VentfortvsCartalax

Molecular Formula

Complex peptide mixture (multiple sequences, MW range up to ₅ kDa; active component KED: C₁₃H₂₂N₄O₇)

Molecular Weight

Complex mixture up to 5,000 Da; KED active tripeptide: ~362.3 g/mol

Half-Life

Short plasma half-life typical of ultrashort peptides (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to vascular gene expression; metabolized to constituent amino acids

Bioavailability

Oral formulation absorbed via intestinal peptide transporters; ultrashort peptides in the complex have efficient cellular uptake; injectable form provides direct systemic delivery; tissue-derived peptides maintain bioactivity through enteric-coated capsule formulation

CAS Number

Not applicable (tissue-derived complex)

Molecular Formula

C₁₂H₁₉N₃O₈

Molecular Weight

333.3 g/mol

Half-Life

Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic gene regulation; metabolized to constituent amino acids

Bioavailability

Orally bioavailable via intestinal peptide transporters (PepT1/PepT2, LAT1); 10-fold more potent than crude cartilage polypeptide complex at chondrogenic activation (200 vs 2000 ng/mL effective concentration)

CAS Number

Not yet registered (research compound)

Common

• Injection site reaction
• Mild fatigue
• Mild headache
• Mild blood pressure fluctuation

Uncommon

• Mild dizziness

Serious

• No documented serious adverse effects

Common

• Mild injection site reaction
• Mild GI discomfort
• Mild fatigue
• Transient joint stiffness

Uncommon

• Temporary increase in joint discomfort

Serious

• No documented serious adverse effects

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Ventfort (collagen peptide complex) demonstrates excellent safety profile from cosmetic and nutritional supplement use spanning decades. Hydrolyzed collagen peptides pass through the GI tract largely unchanged—minimal systemic absorption occurs, making serious adverse effects unlikely. Mild gastrointestinal side effects (bloating, dyspepsia) occur in <5% of users and are generally self-limiting. Allergic reactions are rare given the high molecular weight peptide fragments; histamine content is negligible in properly processed formulations.

Contraindications

• xKnown hypersensitivity to bovine-derived peptide products or any constituent amino acids
• xActive bleeding disorders or concurrent anticoagulant therapy without medical supervision
• xSevere cardiovascular disease requiring immediate medical intervention
• xPregnancy and breastfeeding — insufficient reproductive safety data

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Research compound

Safety Overview

Cartalax (polypeptide complex from bovine cartilage) has not undergone formal FDA approval or rigorous clinical safety trials. The safety profile is based on traditional use in Russia and Eastern Europe as a cartilage extract supplement, with limited published safety data. As a complex mixture of polypeptides, collagens, and proteoglycans, the actual active components and their pharmacology are undefined, making toxicity prediction impossible. Potential allergic reactions to bovine proteins exist, and contamination risks from source animal tissues cannot be ruled out without pharmaceutical manufacturing standards.

Contraindications

• xKnown hypersensitivity to peptide bioregulators or constituent amino acids (alanine, glutamic acid, aspartic acid)
• xPregnancy and breastfeeding — insufficient reproductive safety data
• xActive joint infection — treat infection before initiating peptide bioregulator therapy
• xMalignant bone or cartilage tumors — proliferative effects of peptide bioregulators may be contraindicated